V Square Quantitative Management LLC Purchases 121 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)

V Square Quantitative Management LLC lifted its position in Charles River Laboratories International, Inc. (NYSE:CRL) by 12.6% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,084 shares of the medical research company’s stock after acquiring an additional 121 shares during the quarter. V Square Quantitative Management LLC’s holdings in Charles River Laboratories International were worth $200,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Versant Capital Management Inc lifted its holdings in Charles River Laboratories International by 1,071.4% during the 4th quarter. Versant Capital Management Inc now owns 164 shares of the medical research company’s stock valued at $30,000 after buying an additional 150 shares in the last quarter. Assetmark Inc. increased its position in Charles River Laboratories International by 1,153.3% during the 3rd quarter. Assetmark Inc. now owns 188 shares of the medical research company’s stock valued at $37,000 after purchasing an additional 173 shares during the period. Pinnacle Bancorp Inc. increased its position in Charles River Laboratories International by 52.0% during the 4th quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company’s stock valued at $35,000 after purchasing an additional 65 shares during the period. Wilmington Savings Fund Society FSB purchased a new position in Charles River Laboratories International during the 3rd quarter valued at about $59,000. Finally, ORG Wealth Partners LLC purchased a new position in Charles River Laboratories International during the 4th quarter valued at about $56,000. Institutional investors own 98.91% of the company’s stock.

Charles River Laboratories International Price Performance

Shares of CRL opened at $152.07 on Tuesday. Charles River Laboratories International, Inc. has a 1-year low of $150.79 and a 1-year high of $275.00. The stock has a market cap of $7.78 billion, a PE ratio of 19.03, a P/E/G ratio of 6.47 and a beta of 1.37. The firm has a 50-day simple moving average of $175.44 and a two-hundred day simple moving average of $189.72. The company has a debt-to-equity ratio of 0.61, a current ratio of 1.48 and a quick ratio of 1.14.

Wall Street Analysts Forecast Growth

CRL has been the topic of a number of analyst reports. Bank of America cut their price objective on shares of Charles River Laboratories International from $220.00 to $210.00 and set a “neutral” rating on the stock in a research report on Friday, December 13th. Morgan Stanley dropped their target price on shares of Charles River Laboratories International from $220.00 to $184.00 and set an “equal weight” rating on the stock in a research report on Wednesday, February 5th. UBS Group reissued a “neutral” rating and set a $185.00 target price (down previously from $250.00) on shares of Charles River Laboratories International in a research report on Friday, January 17th. StockNews.com cut shares of Charles River Laboratories International from a “buy” rating to a “hold” rating in a research note on Thursday, November 7th. Finally, TD Cowen lifted their price objective on shares of Charles River Laboratories International from $203.00 to $227.00 and gave the company a “hold” rating in a research note on Monday, November 11th. Three research analysts have rated the stock with a sell rating, thirteen have issued a hold rating and one has given a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $200.79.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).